BCL2L1 and non-Hodgkin lymphoma: In addition to inducing ADCC and CDC, rituximab interferes with the intracellular signal transduction pathway and sensitizes B-NHL cell lines to chemotherapeutic drugs via selective down-regulation of Bcl-2 and Bcl-xl [13], [33].